Inspire Medical Systemsの空売り状況は、投資家がInspire Medical Systemsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Inspire Medical Systems (NYSE:INSP) 株価情報, 空売り情報

Inspire Medical Systems

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems Inc

Inspecs Group PLC

Insperity Inc

Inspira Technologies Oxy B.H.N. Ltd. - Ordinary Shares

Inspira Technologies Oxy BHN Ltd

Inspira Technologies Oxy B.H.N. Ltd. - Warrant

Inspirato Inc

Inspirato Incorporated - Class A Common Stock

Inspire 100 ETF

Inspire Corporate Bond ETF

Inspire Global Hope ETF

Inspire International ETF

INSPIRE SEMICONDUCTOR HLD by INSPIRE SEMICONDUCTOR HLDGS INC.

Inspire Semiconductor Holdings Inc

Inspire Small/Mid Cap ETF

Inspire Tactical Balanced ETF

Inspire Veterinary Partners, Inc. - Class A Common Stock

Inspire Veterinary Partners Inc

InspireMD Inc

Inspired Entertainment, Inc. - Common Stock

Inspired Entertainment Inc

Fearnleys analyst Fredrik Dybwad upgrades SFL Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFL#NYSE">SFL</a>) from Hold to Buy and announces $13 price target.

News

Upgrades

Price Target

Analyst Ratings

Fearnleys Upgrades SFL Corp to Buy, Announces $13 Price Target

William Blair analyst Andy Hsieh downgrades Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) from Outperform to Market Perform.

Downgrades

PYXS

William Blair Downgrades Pyxis Oncology to Market Perform

<a href="https://www.benzinga.com/real-estate/24/06/39534633/new-york-renters-may-benefit-from-huge-potential-change-in-rental-laws">Renters in New York City</a> may feel some relief as the City Council passed legislation eliminating tenant-paid broker fees. For decades, this practice has cost renters thousands of dollars in up-front moving costs.
The Fairness in Apartment Rentals (FARE) Act passed with a veto-proof majority of 42-8, shifting broker fee responsibility to landlords and management companies who hire the agents. The new law will take effect within 180 days of signing.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>
Despite being <a href="https://www.benzinga.com/real-estate/24/05/39091231/rents-are-so-high-in-new-york-city-that-even-135kyear-tech-workers-cant-keep-up">one of the most expensive rental markets in the U.S.</a>, New York City tenants often pay broker fees up to 15% of their first year&#8217;s rent, even when they didn&#8217;t hire the broker. "New Yorkers have been getting ripped off for decades and decades," strategist Bradley Tusk, who pledged $10,000 to support the bill&#8217;s implementation, said in a statement originally reported by the Gothamist.
City Councilmember Chi Ossé introduced the bill and addressed concerns about landlords passing costs to tenants through higher rents. "Forty-seven percent of homes for tenants in New York City are rent-stabilized, so it would be illegal for landlords to bake the fee into rent in that case," Ossé told CBS News.
The real estate industry strongly opposes the change. "The FARE Act, while well-intentioned, is misguided," Ashley Murphy, senior vice president at Brown Harris Stevens, told Realtor.com. "If landlords are forced to pay broker fees, they will likely bake the price into the rent and the lease will be more expensive each and every time a tenant goes to renew."
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
The legislation requires landlords to disclose all tenant fees in rental listings and agreements. Violations carry penalties of up to $1,000 for first offenses and $2,000 for subsequent infractions within two years.
NYC Mayor Eric Adams expressed reservations about the bill&#8217;s impact. "The bill has the right intentions, but sometimes good intentions do not get the results you&#8217;re looking for," Adams said following the vote.
Beyond eliminating broker fees, the law mandates detailed fee disclosures signed by tenants before executing the lease. Landlords must retain the records for three years and provide copies to tenants.
The Department of Consumer and Worker Protection can pursue civil penalties and restitution in court, while individuals maintain the right to bring civil actions over violations.
Read Next:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

'New Yorkers Have Been Getting Ripped Off for Decades': NYC Council Ends Broker Fees For Tenants

Health Care

Legal

General

HROW

Harrow's Subsidiary ImprimisRx Announced A Favorable Jury Verdict In The Case Vs. OSRX Alleging Willful Acts Of Trademark Infringement Against OSRX And Its Related Party, Ocular Science, The $34.9M Verdict Includes $20.4M In Punitive Damages And $14.5M In Actual Damages

CART

Instacart Announces New Supplemental Nutrition Access Program Eligibility Screener Available On EBT SNAP Information Page

The two-story building sits on 2.63 acres and was previously an Extra Space Storage business. It houses a variety of 975 indoor climate-controlled and heated self-storage rooms available for rent at affordable price points. Covered drive-in load/unload areas offer protection from the weather.

UHAL

U-Haul Buys Former Extra Space Storage Facility In Minneapolis; No Terms Disclosed

<ul>
<li>Muddy Waters' latest report is an attempt by a noted short seller to negatively impact e.l.f. Beauty's share price for its own benefit and at the expense of all other e.l.f. Beauty shareholders, and Muddy Waters' allegations are without merit. Muddy Waters has made numerous inaccurate statements about e.l.f. Beauty and our business by relying upon incomplete data and flawed assumptions, omitting critical context, and presenting speculation as fact.</li>
<li>In particular, in early 2024, for competitive reasons and as permitted by applicable regulations, we filed a request for confidentiality with U.S. Customs and Border Protection with respect to our customs import data. Therefore, import data available to the public after February 6, 2024, does not include a substantial majority of our actual U.S. imports.</li>
<li>Further, Muddy Waters' assertions do not align with the strong consumption data published by Nielsen and Circana.</li>
<li>We have rigorous inventory control procedures, including regular physical and cycle counts across our global distribution network. Similarly, we have rigorous controls and procedures around revenue recognition. We are fully confident in our financial statements.</li>
<li>Our recently announced second quarter fiscal 2025 financial results – marking our 23rd consecutive quarter of both net sales growth and market share gains – demonstrate our strong momentum and underscore our confidence in our business model and strategy. e.l.f. Beauty continues to deliver consistent, category leading growth.</li>
</ul>

Short Sellers

e.l.f. Beauty Issued A Statement In Response To A Report Published By Muddy Waters Research Saying  Allegations Are Without Merit; Company Is Fully Confident In Financial Statements

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Buy and raises the price target from $32 to $37.

KURA

HC Wainwright & Co. Maintains Buy on Kura Oncology, Raises Price Target to $37

Biotech

QURE

uniQure Has Dosed The First Patient In GenTLE Phase 1/2a Trial Of AMT-260 For Refractory Mesial Temporal Lobe Epilepsy

Kong-Picarello will join Terex on February 3, 2025 and assume her duties as Chief Financial Officer of Terex later in February shortly after Terex files its 2024 Annual Report on Form 10-K.&nbsp;
Beck will remain in her current role until Ms. Kong-Picarello assumes the duties of Chief Financial Officer. Beck will then continue with the Company until April 1 to assist with the transition.

Management

Terex Names Jennifer Kong-Picarello To Succeed Julie Beck As Senior Vice President And CFO

Arthur J. Gallagher Acquired Santiago, Chile-based THB Chile, Deal Terms Were Not Disclosed

UBS analyst Alex Kramm initiates coverage on Broadridge Financial Soln (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) with a Neutral rating and announces Price Target of $250.

Initiation

UBS Initiates Coverage On Broadridge Financial Soln with Neutral Rating, Announces Price Target of $250

First Quarter and Full Year Fiscal 2025 Outlook
For the fiscal quarter ending December 31, 2024, revenue is expected to be in the range of $47 million to $50 million. GAAP net loss is expected to be in the range of ($26) million to ($23) million. Adjusted EBITDA is expected to be in the range of ($9) million to ($6) million.
For the full fiscal year ending September 30, 2025, the company expects revenue to be in the range of $236 million to $247 million which includes an estimated $20 million of fixed contracts at the mid-point of guidance. GAAP net loss is expected to be in the range of ($40) million to ($29) million. Adjusted EBITDA is expected to be in the range of $15 million to $26 million.

Guidance

CRNC

Cerence Expects Q1 Revenue Of $47M-$50M Vs $47.65M Est, FY25 Revenue Of $236M-$247M Vs $324.34M Est

Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, which disrupt the rapid cell division exhibited by cancer cells.
The new HFE arrays utilize a flexible polymer material in place of the ceramic discs used in the current Optune Gio arrays, making them one-third lighter and 50% thinner.

NVCR

The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of 2025 Through A Controlled Transition Plan

TRNR

Interactive Strength  Board Approves Maximum Cumulative Bitcoin Purchase Of Up To $5M;  Plans To Accept Payment In Digital Currencies

Earnings

CATO

Cato Q3 EPS $(0.79) Down From $(0.30) YoY, Sales $144.6M Down From $156.7M YoY

UBS analyst A.J. Rice initiates coverage on Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Buy rating and announces Price Target of $175.

ENSG

UBS Initiates Coverage On Ensign Group with Buy Rating, Announces Price Target of $175

Wedbush analyst Nick Setyan reiterates Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Outperform and maintains $50 price target.

Reiteration

JACK

Wedbush Reiterates Outperform on Jack In The Box, Maintains $50 Price Target

Benjamin Kovler, Chairman and Interim Chief Executive Officer, participated in the private placement to purchase 10,000 shares of common stock at a purchase price of $38.76.

Financing

AGFY

Agrify Announced A Non-brokered Private Placement Priced At $22.30 Per Share For Aggregate Proceeds Of Approximately $25.9M

Company Outlook &amp; Summary
Net income attributable to Deere&nbsp;&amp; Company for fiscal 2025 is forecasted to be in a range of $5.0&nbsp;billion to $5.5 billion.
"As we navigate ongoing headwinds across our markets, we remain committed to making meaningful investments in our future while deepening our relationships with customers," May continued. "Our team of over 75,000 dedicated employees come to work each day with a singular focus: delivering products and solutions that enhance efficiency and reduce operating costs for our customers. By providing the essential tools they need, we empower our customers to succeed and thrive in an ever-evolving and challenging landscape."

Deere & Company Projects Fiscal 2025 Net Income Between $5B-$5.5B

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on INSP stock, giving a Buy rating yesterday. Anthony Petrone's ratin...

Inspire Medical Systems: Strong Performance and Growth Potential Highlighted by Positive Indicators and Strategic Opportunities

Leerink Partners analyst Mike Kratky reiterated a Hold rating on Inspire Medical Systems (INSP – Research Report) on November 4 and set a price tar...

Inspire Medical Systems: Mixed Signals Lead to Hold Rating Amid Utilization and Competitive Challenges

Columbia Acorn Fund Q3 2024 Investment Commentary

Inspire Medical enters $75M accelerated share repurchase agreement

Lake Street analyst Frank Takkinen reiterated a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of $270...

Lake Street Remains a Buy on Inspire Medical Systems (INSP)

Baird Q3 2024 Small/Mid Cap Growth Equity Fund Commentary

Fidelity OTC Portfolio Fund Q2 2024 Review

BofA upgraded Inspire Medical (INSP) to Buy from Neutral with a $255 price target Published first on TheFly – the ultimate source for real-time, ma...

Inspire Medical upgraded to Buy from Neutral at BofA

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Target downgraded, Chewy upgraded: Wall Street's top analyst calls

Inspire Medical upped to buy by BoA, improved margins cited

AAON

AAPL

ACLS

ALAB

ALNY

APPF

ASML

ASMLF

ATKR

AVGO

BESIY

BESVF

BOOT

BROS

BURL

BWXT

CACI

CASY

CAVA

CHDN

CHWY

CIGI

CPRI

CWAN

CYBR

EXAS

EXLS

FANG

FIVE

FOUR

FTAI

FTAIO

GOOG

GOOGL

INGM

INSP

INTC

IRTC

JKHY

KNSL

LGIH

LMND

LSCC

MANH

MEDP

MNDY

MRVL

NBIX

NFLX

NTRA

NVDA

ONTO

PCOR

PODD

POOL

PRCT

QCOM

RMBS

RXST

SEDG

SITM

SMCI

SMPL

SPXC

TARS

TECH

TOST

TREX

TSLA

TSMWF

VNOM

Press Releases

Inspire Medical Systems, Inc. Announces Second Quarter 2024 Financial Results and Updates 2024 Outlook

Inspire Medical Systems, Inc. to Present at Upcoming Investor Conferences

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Inspire Medical Systems, Inc. to Report Third Quarter 2024 Financial Results on November 4, 2024

Inspire Medical Systems, Inc. to Present at UBS Global Healthcare Conference

Inspire Medical Systems, Inc. Announces Third Quarter 2024 Financial Results and Updates 2024 Outlook

Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference

Inspire Medical Systems, Inc. Announces $75 million Accelerated Share Repurchase Program

UPDATED – Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference

Inspire Medical Systems, Inc. to Present at Piper Sandler 36th Annual Healthcare Conference

Comments

Inspire Medical Systems

空売り

Inspire Medical Systems (NYSE:INSP) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル